Answers are grounded in this paper and cite their sources.
Reduction in drinking (not only abstinence) has been included as a secondary outcome measure in most clinical trials for alcohol use disorder (AUD). Still reduction in drinking was never a formally approved treatment goal for AUD in clinical trials used for drug approval by the US Food and Drug Administration (FDA). Using only total abstinence as the only valid treatment outcome has led to an undeserved negative attitude towards the treatment of AUD in general, as many do not reach this goal, be it because they do not want or need to. Also, as many drugs for the treatment of AUD do not promote total abstinence, but controlled drinking, accepting only total abstinence as outcome has made it difficult to appreciate to factual continuation of these drugs.A total abstinence model has deep historical roots but was reinforced by the AA-movement and the 12-step model originating in the 1930-ties [1]. The idea that recovering from AUD or indeed any substance use disorder (SUD) involves total abstinence, has helped many people out of their addiction problems. This has involved acknowledging the overwhelming power of addictions and facing the problems head on. Conversely, less rigid alternatives have been viewed harm reduction, some people supporting this, while others look at it as a suboptimal solution or even giving up. However, research has shown that lifelong abstinence is not “the only right way.” In fact, most former heavy drinkers return to controlled drinking [2], at least those least troubled among nontreatment seeking or less severely affected individuals [3].The FDA now formally recognizes a ≥2-level reduction in World Health Organization (WHO) Risk Drinking Levels as a clinically meaningful primary endpoint for pharmacological trials in moderate to severe AUD. This signals a new attitude from the US side [4] and paves their way for a sentiment shared by many who believe that total abstinence is not the only way out of addiction. It may not seem like a major change, especially from a European point of view, but it is. This new approach harmonizes US regulatory expectations with European Medicines Agency (EMA) and is founded on robust evidence that such reductions confer substantial health benefits and are feasible for a larger proportion of patients [5].The scientific base includes a review of 27 observational studies that demonstrates that a reduction in WHO’s risk drinking levels is associated with lower odds of alcohol dependence, significant improvements in physical health markers (e.g., liver function), fewer psychiatric symptoms, better quality of life, reduced health care utilization, and improved functioning [5]. The review also includes seven pharmacotherapy trials that show that medications like nalmefene, naltrexone, topiramate, and varenicline decrease rates of significant alcohol intake, with these endpoints showing greater sensitivity to medication effect than abstinence-based outcomes.This groundbreaking review by Witkiewitz et al. [5] is the result from the ACTIVE consortium formed in 2012 as a public-private partnership, bringing together academic investigators, pharmaceutical sponsors (19 companies over time), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the FDA. This may seem to be an unlikely alliance between the pharmaceutical industry, some user organizations, and harm reduction enthusiasts. We know that the alcohol industry will promote controlled drinking over abstinence [6] and furthermore that these initiatives in practice do no promote less drinking [7]. These industry initiatives, however, have little or no preventive effect. Still, from a medical point of view, it is never wrong to reduce harm. A focus on abstinence (“full recovery”) also contrasts what is expected in other psychiatry domains, e.g., depression or psychosis, where symptom reduction, increased functioning or fewer hospitalizations are taken as valid primary outcome goals in psychopharmacological trails.Anton and co-workers highlight in their commentary that the ACTIVE workgroup’s multi-year analyses of both population and clinical trial data find that nearly all patient-centred variables (physical, social, mental health) improve with drinking reduction. In three well-controlled phase III trials, the WHO approved drinking reduction outcome yielded comparable or larger effect sizes than abstinence or heavy drinking endpoints and resulted in higher overall response rates – improving the public health impact and facilitating broader patient access to treatment [8].Acceptance of reductions in drinking as a clinically meaningful goal can help close the AUD treatment gap, research indicating that only one in six patients receive adequate treatment [4]. Patients often resist care when abstinence is the only success measure; allowing harm reduction endpoints validates more attainable and personally relevant goals, likely increasing treatment uptake and clinician engagement [4]. The broader definition of success may foster development, testing, and approval of novel medications, improve global harmonization of clinical trials, and catalyze greater use of currently available compounds for patients whose primary goal is reduction rather than abstinence.The FDA decision may signify a paradigm shift within AUD treatment and research, grounded in decades of accumulated data and collaborative regulatory innovation. The ruling promises to improve the clinical relevance of trials, enable truly patient-centred approaches, foster innovation, and expand access to care for individuals with AUD.It is important to remember that AUD is not one disorder but represents numerous many endophenotypes that represent different forms of addiction, and probably different treatment demands [9, 10]. The years ahead will teach us more about who needs to have what goal and how it can be achieved. Obviously further research is needed on the sensitivity of WHO’s drinking level reductions compared with continuous endpoints (e.g., percent heavy drinking days), the impact on special populations (e.g., people with severe liver disease, adolescents, or individuals with major psychiatric comorbidities), outcomes for those starting at lower risk levels, and the real-world applicability in routine clinical care and prevention strategies. Finally, and from a broader perspective we applaud the FDA’s consequent approach, i.e., translating sound scientific evidence to an important policy decision that will have a major impact on AUD treatment and broader public health.Prof. Dr. med. Jørgen G. Bramness and Prof. Geert Dom were members of the journal’s Editorial Board at the time of submission. None of the authors have any commercial conflicts of interest to report.This study was not supported by any sponsor or funder.Jørgen G. Bramness and Geert Dom both contributed to the conceptualization of this editorial and contributed equally to the review and editing of the final contribution. Jørgen G. Bramness wrote the original draft.Jørgen G. Bramness and Geert Dom both belong to the European Federation of Addiction Societies (EUFAS).
No takes yet. Share an insight, caveat, or question.
Bramness et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: